Johnson & Johnson stock holds near record earnings scale

Johnson & Johnson (US4781601046) is supported by 2025 revenue of $88.8 billion and 2025 net earnings of $14.7 billion, while the company also reported a 11.9% decline in vaccine sales in Q4 2025. The stock closed at a market capitalization level that remains large enough to keep the name central in health care portfolios, with the latest visible market figure omitted here because no dated quote was available in the search results.

2025 earnings stay the anchor

Johnson & Johnson reported full-year 2025 revenue of $88.8 billion, compared with $85.2 billion in 2024, which implies growth of about 4.2%. Net earnings came to $14.7 billion in 2025, down from $35.2 billion in 2024 because 2024 included an unusually large gain from the Kenvue separation transaction.

That comparison matters more than the headline level. It shows that the company's income base is still broad, but the year-on-year earnings trend is distorted by one-off items, making revenue and operating segment performance more useful than net profit alone.

Vaccine sales fell 11.9%

In Q4 2025, vaccine sales fell 11.9% year over year, while the company still posted adjusted operational sales growth across several larger health care franchises. The decline is a reminder that Johnson & Johnson's mix is not uniform and that one product category can move the quarter even when the group remains diversified.

For investors tracking the next leg of the story, the key point is not a single quarter's headline, but the balance between growth in pharmaceuticals and medical technology and softer areas such as vaccines. That mix determines whether revenue growth can keep outpacing the lower-growth parts of the health care market.

Cash generation remains visible

Johnson & Johnson generated $19.8 billion of cash from operations in 2025, a figure that supports dividends, research spending, and balance-sheet flexibility. Free cash flow also stayed strong enough to keep capital returns intact, even as the company continued to manage litigation and restructuring items.

The cash figure matters because it gives the company room to fund its pipeline while still returning capital. For a large-cap health care stock, that combination usually matters more to the market than short-term noise around any one product line.

Darzalex still matters

One of the most important product references in the company portfolio is Darzalex, which remained a major oncology driver in 2025. Alongside Stelara, Tremfya, and Carvykti, it helped offset weaker areas elsewhere in the business and kept the pharmaceuticals division central to the investment case.

The product mix also explains why segment-level numbers matter. In a company of Johnson & Johnson's size, one branded medicine can contribute materially to total sales momentum, but the broader base is what sustains earnings quality over time.

Market value and venue

Johnson & Johnson trades on the New York Stock Exchange, and its scale still places it among the most closely watched health care names in the US market. The stock narrative today is tied less to speculation than to the durability of revenue, operating cash flow, and the next set of segment results.

As a practical market marker, the latest dated quote was not available in the search results, so the article uses the stronger evidenced reference point: 2025 revenue of $88.8 billion, 2025 net earnings of $14.7 billion, and 2025 cash from operations of $19.8 billion. Those three figures give a fuller picture of the stock than an unverified intraday tick would have done.